Perfosfamide

Drug Profile

Perfosfamide

Alternative Names: 4-HC; NSC 181815; Pergamid

Latest Information Update: 23 Aug 2001

Price : $50

At a glance

  • Originator MGI Pharma
  • Developer MGI Pharma; SuperGen
  • Class Antineoplastics; Phosphoramide mustards; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Leukaemia

Most Recent Events

  • 23 Aug 2001 NCI to fund a phase III study in AML patients in the US
  • 24 Jan 1995 Discontinued-II for Leukaemia (myeloablation) in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top